These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 34449067)
21. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dai C; Wang YN; Tian WN; Huang YH; Jiang M Int Immunopharmacol; 2022 Nov; 112():109269. PubMed ID: 36182873 [TBL] [Abstract][Full Text] [Related]
22. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570 [TBL] [Abstract][Full Text] [Related]
23. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475 [TBL] [Abstract][Full Text] [Related]
24. The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ni R; Zheng J; Varghese J; Kumar B Cureus; 2024 May; 16(5):e60980. PubMed ID: 38910708 [TBL] [Abstract][Full Text] [Related]
25. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934 [TBL] [Abstract][Full Text] [Related]
26. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462 [TBL] [Abstract][Full Text] [Related]
27. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease. Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288 [TBL] [Abstract][Full Text] [Related]
28. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924 [TBL] [Abstract][Full Text] [Related]
29. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature. Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037 [TBL] [Abstract][Full Text] [Related]
31. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479 [TBL] [Abstract][Full Text] [Related]
32. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Garg SK; Croft AM; Bager P Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009400. PubMed ID: 24442917 [TBL] [Abstract][Full Text] [Related]
33. Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated With Biologic Agents Determined Using the BSRBR-AS and a MetaAnalysis. Macfarlane GJ; Biallas R; Dean LE; Jones GT; Goodson NJ; Rotariu O J Rheumatol; 2023 Feb; 50(2):175-184. PubMed ID: 35777821 [TBL] [Abstract][Full Text] [Related]
34. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. Esse S; Mason KJ; Green AC; Warren RB JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649 [TBL] [Abstract][Full Text] [Related]
36. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765 [TBL] [Abstract][Full Text] [Related]
37. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708 [TBL] [Abstract][Full Text] [Related]
38. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis. Miao XP; Ouyang Q; Li HY; Wen ZH; Zhang DK; Cui XY Curr Ther Res Clin Exp; 2008 Jun; 69(3):181-91. PubMed ID: 24692797 [TBL] [Abstract][Full Text] [Related]
39. Visceral adiposity and inflammatory bowel disease. Rowan CR; McManus J; Boland K; O'Toole A Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989 [TBL] [Abstract][Full Text] [Related]